Ivanka
Ivanka Atanasova-Hoehlein, Fuerth DE
Patent application number | Description | Published |
---|---|---|
20110220552 | METHOD FOR REMOVING CORROSIVE SULFUR COMPOUNDS FROM A TRANSFORMER OIL - A method removes corrosive sulfur compounds from transformer oil. By adding a mixture of rare earths containing aluminum oxide and aluminum silicate to the transformer oil, and enriching the same with an aqueous solution of soluble metal salts, the corrosive sulfur compounds in the transformer oil are neutralized with defined heating and cooling phases. Advantageously, no additional chemical components, such as passivators, are added to the transformer oil. When using a tank for receiving the mixture of the rare earths containing aluminum oxide and aluminum silicate, the reaction can run in the tank. Any aging products that may be present, and the bonded corrosive sulfur compounds are effectively retained within the tank by a filter system, and can be disposed of with the tank. | 09-15-2011 |
Ivanka Atanasova-HÖhlein, Fuerth DE
Patent application number | Description | Published |
---|---|---|
20120076926 | METHOD FOR PRODUCING AN ELECTRICAL CONDUCTOR WITH AN INSULATION AND AT LEAST ONE POINT TO BE KEPT FREE OF THE INSULATION - The conductor, including the points being kept free insulation, is initially surrounded by a liquid, electrically non-conducting bonding agent which forms the insulation after solidifying. The conductor can be a transposed conductor in which the individual conductors thereof are electrically isolated relative to each other and are interconnected by the bonding agent. Using a liquid stripping agent based on a polyvinyl alcohol or a long-chain hydrocarbon mixture and a polysaccharide filler on the point of the conductor being kept free of the insulation locally prevents the bonding agent from bonding to the conductor or the individual conductors of the transposed conductor from being interconnected by means of the unsolidified mixture. Once the entire bonding agent is hard and thus the bonding agent/stripping agent mixture has solidified, the bonding agent/stripping agent mixture can easily be removed in a mechanical manner from the treated points of the conductor. | 03-29-2012 |
Ivanka Jarska, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150238515 | ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES - The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS. | 08-27-2015 |
Ivanka Jeric, Zagreb HR
Patent application number | Description | Published |
---|---|---|
20110213566 | Method Of And System For Blind Extraction Of More Than Two Pure Components Out Of Spectroscopic Or Spectrometric Measurements Of Only Two Mixtures By Means Of Sparse Component Analysis - A method, system, and computer program product for identification of more than two pure components from two mixtures using sparse component analysis. Spectroscopic data for two mixtures X are analyzed in a recording domain or in a first new representation domain by using linear transform T | 09-01-2011 |
20110229001 | METHOD OF AND SYSTEM FOR BLIND EXTRACTION OF MORE PURE COMPONENTS THAN MIXTURES IN 1D AND 2D NMR SPECTROSCOPY AND MASS SPECTROMETRY COMBINING SPARSE COMPONENT ANALYSIS AND SINGLE COMPONENT POINTS - A computer-implemented data processing system for blind extraction of more pure components than mixtures recorded in 1D or 2D NMR spectroscopy and mass spectrometry. Sparse component analysis is combined with single component points (SCPs) to blind decomposition of mixtures data X into pure components S and concentration matrix A, whereas the number of pure components S is greater than number of mixtures X. NMR mixtures are transformed into wavelet domain, where pure components are sparser than in time domain and where SCPs are detected. Mass spectrometry (MS) mixtures are extended to analytical continuation in order to detect SCPs. SCPs are used to estimate number of pure components and concentration matrix. Pure components are estimated in frequency domain (NMR data) or m/z domain (MS data) by means of constrained convex programming methods. Estimated pure components are ranked using negentropy-based criterion. | 09-22-2011 |
20150206727 | Method and apparatus for underdetermined blind separation of correlated pure components from nonlinear mixture mass spectra - The present invention relates to a computer-implemented method and apparatus for data processing for the purpose of blind separation of nonnegative correlated pure components from smaller number of nonlinear mixtures of mass spectra. More specific, the invention relates to preprocessing of recorded matrix of mixtures spectra by robust principal component analysis, trimmed thresholding, hard thresholding and soft thresholding; empirical kernel map-based nonlinear mappings of preprocessed matrix of mixtures mass spectra into reproducible kernel Hilbert space and linear sparseness and nonnegativity constrained factorization of mapped matrices therein. Thereby, preprocessing of recorded matrix of mixtures mass spectra is performed to suppress higher order monomials of the pure components that are induced by nonlinear mixtures. Components separated by each factorization are correlated with the ones stored in the library. Thereby, component from the library is associated with the separated component by which it has the highest correlation coefficient. Value of the correlation coefficient indicates degree of pureness of the separated component. Separated components that are not assigned to the pure components from the library can be considered as candidates for new pure components. Identified pure components can be used for identification of compounds in chemical synthesis, food quality inspection or pollution inspection, identification and characterization of compounds obtained from natural sources (microorganisms, plants and animals), or in instrumental diagnostics—determination and identification of metabolites and biomarkers present in biological fluids (urine, blood plasma, cerebrospinal fluid, saliva, amniotic fluid, bile, tears, etc.) or tissue extracts. | 07-23-2015 |
Ivanka Kolenc, Novo Mesto SI
Patent application number | Description | Published |
---|---|---|
20090149657 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF CHLORAMPHENICOL OR ITS ANALOGUES - The present invention relates to the synthesis of antibacterial compounds such as Chloramphenicol and its analogues Thiamphenicol and Florfenicol and particularly to a new reaction for the preparation of the intermediate compound aminodiolphenylsulfone. This reaction permits the introduction of modified residues to obtain modified antibiotics with an improved stability towards the action of bacterial resistant determinants. In addition, higher purities may be also obtained due to an improved procedure requiring fewer purification steps. | 06-11-2009 |
20100105908 | Process For The Preparation Of Levocetirizine And Intermediates Thereof - The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process. | 04-29-2010 |
20110319395 | Pharmaceutical Formulation of Olanzapine - A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients. | 12-29-2011 |
20130171212 | Stable Aqueous Formulations Comprising Poorly Water Soluble Active Ingredients - A formulation includes one or more active ingredients of poor water solubility for medical or non-medical use in the rearing of animals. The formulation is suitable for administration to the animals via their drinking water. It exhibits superior stability. The formulation comprises an active ingredient, a thickener combination and water, wherein the thickener combination comprises at least one thickener selected from the following groups A, B, C and D: | 07-04-2013 |
Ivanka Milcheva, Bayreuth DE
Patent application number | Description | Published |
---|---|---|
20080318091 | METHOD AND SYSTEM OF OPERATING A HIGH-TEMPERATURE FUEL CELL - The invention relates to a method and to a system of operating a high-temperature fuel cell. At least one fuel cell, a reformer, an afterburner and a heat exchanger are present in the system. The total efficiency should be increased with the invention in accordance with the object set. In accordance with the invention, for this purpose, fresh air supplied to the fuel cell(s) at the cathode side is preheated in multiple stages by heat from the afterburning and from the heated air dissipated from the fuel cell(s) at the cathode side by means of a high-temperature heat exchanger. | 12-25-2008 |
Ivanka Poljak, Stuttgart DE
Patent application number | Description | Published |
---|---|---|
20160051918 | Filter Medium, Particularly an Air Filter Medium and Filter Element, Particularly an Air Filter Element, Having a Filter Medium - A filter medium is provided with a first filter layer and a second filter layer that is arranged downstream of the first filter layer in a flow-through direction of the filter medium and has nanofibers. The first filter layer has a first filter layer section and a second filter layer section, wherein the second filter layer section is arranged downstream of the first filter layer section in the flow-through direction of the filter medium. The first filter layer section has a first packing density of fibers and the second filter layer section has a second packing density of fibers deviating from the first packing density of fibers. | 02-25-2016 |
Ivanka Terzic, Vienna AT
Patent application number | Description | Published |
---|---|---|
20110093800 | HMI FRAMEWORK FOR EXTENSIBLE AUTOMATION SYSTEM ENGINEERING PLATFORMS - A GUI framework leverages interfaces of extensible engineering platforms to provide a tool that easily constructs HMIs for automation systems. The GUI framework can import existing GUI components and/or create new GUI components. The GUI framework can also combine basic GUI components to create complex composite GUI components. An import mechanism can also be employed to import existing GUI components by encapsulating them in common, reusable software code that is compatible with an extensible engineering platform. The GUI framework utilizes function blocks to represent the GUI components and automatically generates GUI function block networks with linking as required. This allows complex GUIs to be created with minimal user effort. | 04-21-2011 |
Ivanka Toudjarska, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20130317081 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. | 11-28-2013 |
20140142162 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes - The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides. | 05-22-2014 |
Ivanka Toudjarska, Medford, MA US
Patent application number | Description | Published |
---|---|---|
20100087508 | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 04-08-2010 |
20100168206 | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 07-01-2010 |
20120282341 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 11-08-2012 |
20130012570 | GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 01-10-2013 |
20130023577 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 01-24-2013 |
20140194489 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6. | 07-10-2014 |
20140336243 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 11-13-2014 |
20150099794 | GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 04-09-2015 |
20160000819 | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 01-07-2016 |
20160024499 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes - The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. | 01-28-2016 |